sanjeriRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company focused on discovering and commercializing innovative therapeutics for hematological conditions and cancers. RIGL’s main FDA-approved products are Tavalisse, Rezlidhia, and Gavreto. Tavalisse targets SYK, Rezlidhia rrAML, and Gavreto NSCLC. In my analysis, I conclude that RIGL’s current valuation seems quite undervalued relative to its peers, particularly considering that it has a reasonable pathway toward becoming cash flow pos ...